Navigation Links
Akela Pharma Inc. Completes Share Consolidation
Date:10/9/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Oct. 9 /PRNewswire-FirstCall/ - AKELA Pharma Inc., (TSX: AKL), a drug development company focused on developing therapies for the inhalation, pain and CNS markets, today announced that effective October 10, 2007, its issued and outstanding common shares will be consolidated on the basis of one (1) post-consolidation common share for every seven (7) pre-consolidation common shares. Fractional interests will be paid in cash in U.S. dollars for shareholders other than those in Canada who will be paid in Canadian dollars. The common shares will commence trading on the Toronto Stock Exchange on a post-consolidated basis at the opening of trading on October 10, 2007.

The share consolidation has been effected to satisfy the NASDAQ's listing criteria regarding minimum bid price. After the share consolidation, the Company will have approximately 11.75 million common shares outstanding. The stock symbol of the Company will remain AKL on the TSX.

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation, pain and CNS markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent formulations.

Akela's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "AKL" with 82.3 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of AKELA Pharma Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.


'/>"/>
SOURCE Akela Pharma Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. India to benefit from pharma companies move
2. South Africa Wins landmark case against pharmaceutical giants
3. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
4. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
5. Pharma cos must forge Strategic alliances
6. Jharkhand Pharmacies Refuse To Sell Viagra
7. Setting up a new pharmaceutical industry in India
8. Medicis Pharmaceutical company enters pediatric market
9. Supply of Radiopharmaceuticals Hampered by Attacks
10. Pharma majors gear to supply anti-anthrax drug
11. Pharmacies in for a dose of bitter medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... Using the power of ... a simple online checklist. Over a period of just 24 months, thousands of individuals ... an online checklist called T.A.D. , “The internet is not getting quieter. In fact ...
(Date:2/22/2017)... ... February 22, 2017 , ... ANGLESTRONG , the new recovery ... available on the App Store and Google Play . Florida-based Sober ... addiction and recovery industry, partnered with Angle to build ANGLESTRONG. The new recovery management ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... related to spine practices, is featuring Michigan neurosurgeon Jay Jagannathan, M.D., as a ... of a small number of neurosurgeons in Michigan performing minimally invasive back surgery ...
(Date:2/22/2017)... PA (PRWEB) , ... February 22, 2017 , ... A ... some people seem to derive a heart-protective benefit from eating soy foods, while others ... , Japanese men who are able to produce equol—a substance made by some types ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... hearing and 72 percent of those report that family members or friends have ... think they suffer from hearing loss wear hearing aids. One reason, suggested by ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... 2017  Bioness, Inc., the leading provider of cutting ... series of successful StimRouter Neuromodulation System implantations in ... (Nijmegen, Netherlands ), South ... ), and Kliniek Park Leopold Chirec ( Brussels, ... plans to further support clinicians across the continent who ...
(Date:2/22/2017)... Colo. , Feb. 22, 2017  Aytu BioScience, ... global commercialization of novel products in the field of ... team to up to 42 account managers from 35 ... The sales force expansion is being ... prescriptions and revenues, an indication of increasing acceptance of ...
(Date:2/22/2017)... -- According to a new market research report "Process Analytical ... Services (Analyzers, Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO & ... is poised to reach USD 3.30 Billion by 2021 from USD 1.77 ... Continue Reading ... ...
Breaking Medicine Technology: